{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:05:31Z","timestamp":1777421131042,"version":"3.51.4"},"reference-count":61,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the clinical presentation of transthyretin amyloid cardiomyopathy (ATTR-CM) and discuss current treatments and investigational products and their effect on patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed in PubMed (September 2018 to December 2020) using the following keywords: transthyretin amyloidosis, cardiomyopathy, polyneuropathy and transthyretin amyloid cardiomyopathy, monoclonal light-chain, tafamidis, cardiac amyloidosis, ATTR cardiomyopathy, green tea and inhibition of cardiac amyloidosis, AG10, tolcapone, tolcapone and leptomeningeal ATTR, PRX004, NI006, patisiran, inotersen, vutrisiran, AKCEA-TTR-LRx, and NTLA-2001.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Clinical trials were evaluated for evidence supporting pharmacology, safety, efficacy, and measured outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Until 2019, there were no approved treatments for ATTR-CM. Treatment consisted of symptom management and organ transplant. Nonpharmacological and pharmacological treatments focused on the symptoms of heart failure (HF) associated with ATTR-CM. However, there are several emerging therapies recently approved or in development to address the underlying pathophysiology. Treatment classes for ATTR-CM include transthyretin stabilizers, human monoclonal antibodies, gene silencers, and CRISPR\/Cas9 gene editing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>ATTR-CM is a complex disease in which amyloidosis causes cardiomyopathy. Underdiagnosis is attributed to the clinical presentation being heterogeneous, indistinguishable from HF caused by other etiologies, and the need for invasive testing modalities, including endomyocardial biopsy. Improved diagnostic approaches along with targeted therapies can slow disease progression and enhance patient quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Diagnostic modalities along with biomarker and genetic testing could detect disease earlier and target therapy more accurately. Novel therapies demonstrate potential treatment benefits and can help shape the standard of care for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280211000351","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T04:38:56Z","timestamp":1615264736000},"page":"1502-1514","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Transthyretin Amyloid Cardiomyopathy\u2014Current and Future Therapies"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0379-4451","authenticated-orcid":false,"given":"Jankhna D.","family":"Yadav","sequence":"first","affiliation":[{"name":"Pfizer, Inc, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harjot","family":"Othee","sequence":"additional","affiliation":[{"name":"Pfizer, Inc, Groton, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Chan","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damen C.","family":"Man","sequence":"additional","affiliation":[{"name":"Pfizer, Inc, Kirkland, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul P.","family":"Belliveau","sequence":"additional","affiliation":[{"name":"MCPHS University, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Towle","sequence":"additional","affiliation":[{"name":"MCPHS University, Manchester, NH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"bibr1-10600280211000351","unstructured":"MedlinePlus. TTR gene\u2014transthyretin. Accessed July 25, 2019. https:\/\/ghr.nlm.nih.gov\/gene\/TTR"},{"key":"bibr2-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"bibr3-10600280211000351","unstructured":"Pfizer. U.S. FDA approves VYNDAQEL\u00ae and VYNDAMAX\u2122 for use in patients with transthyretin amyloid cardiomyopathy, a rare and fatal disease. Accessed May 9, 2019. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease"},{"key":"bibr4-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"bibr5-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.04.007"},{"key":"bibr6-10600280211000351","unstructured":"American College of Cardiology. ATTR-ACT: tafamidis findings offer hope for patients with ATTR-CM. Accessed May 29, 2019. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2018\/08\/22\/14\/15\/mon-5am-attr-act-esc-2018"},{"key":"bibr7-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.07.170"},{"key":"bibr8-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"bibr9-10600280211000351","unstructured":"American Heart Association. What is transthyretin amyloid cardiomyopathy (ATTR-CM)? Accessed May 29, 2019. https:\/\/www.heart.org\/-\/media\/files\/health-topics\/answers-by-heart\/what-is-attrcm.pdf?la=en"},{"key":"bibr10-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2019.12.034"},{"key":"bibr11-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"bibr12-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.593"},{"key":"bibr13-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"bibr14-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000547"},{"key":"bibr15-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-014-9462-7"},{"key":"bibr16-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2017.05.036"},{"key":"bibr17-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0463-z"},{"key":"bibr18-10600280211000351","unstructured":"Markham H. Amyloidosis: what it is, what causes it, and how rare this condition is. Accessed May 30, 2019. https:\/\/www.everydayhealth.com\/amyloidosis"},{"key":"bibr19-10600280211000351","unstructured":"Witteles R. Cardiac amyloidosis. Accessed May 30, 2019. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2016\/07\/07\/14\/59\/cardiac-amyloidosis"},{"key":"bibr20-10600280211000351","unstructured":"Coelho T, Ericzon B, Falk R, et al. A guide to transthyretin amyloidosis. Accessed June 2, 2019. http:\/\/www.amyloidosis.org\/wp-content\/uploads\/2017\/05\/2017-ATTR-guide.pdf"},{"key":"bibr21-10600280211000351","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-8-3-8"},{"key":"bibr22-10600280211000351","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.84.s3.02"},{"key":"bibr23-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2016.12.003"},{"key":"bibr24-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12383"},{"key":"bibr25-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1002\/msj.21352"},{"key":"bibr26-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"bibr27-10600280211000351","unstructured":"Dolobid. Package insert. Merck & Co Inc; 2005. Accessed February 8, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/018445s058lbl.pdf"},{"key":"bibr28-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.075"},{"key":"bibr29-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2016.1269739"},{"key":"bibr30-10600280211000351","unstructured":"Pfizer. Safety and efficacy of tafamidis in patients with transthyretin cardiomyopathy (ATTR-ACT). Accessed August 5, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01994889?term=Tafamidis&cond=TransthyretinAmyloidCardiopathy&rank=2"},{"key":"bibr31-10600280211000351","unstructured":"Vyndaqel and Vyndamax. Package insert. Pfizer Inc; 2019. Accessed September 15, 2019. https:\/\/www.fda.gov\/media\/126283\/download"},{"key":"bibr32-10600280211000351","unstructured":"Center for Drug Evaluation and Research. Summary Review for regulatory action\u2014NDA 211996\/NDA 212161 (tafamidis meglumine\/free acid). Accessed December 4, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211996Orig1s000,%20212161Orig1s000SumR.pdf"},{"key":"bibr33-10600280211000351","unstructured":"Onpattro. Package insert. Alnylam Pharmaceuticals Inc; 2018. Accessed October 15, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210922s000lbl.pdf"},{"key":"bibr34-10600280211000351","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S87945"},{"key":"bibr35-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"bibr36-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.07.043"},{"key":"bibr37-10600280211000351","unstructured":"Tegsedi. Package insert. Akcea Therapeutics Inc; 2019. Accessed October 15, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211172lbl.pdf"},{"key":"bibr38-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"bibr39-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10787"},{"key":"bibr40-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1597702"},{"key":"bibr41-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.06.011"},{"key":"bibr42-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"bibr43-10600280211000351","unstructured":"AP NEWS. Eidos Therapeutics announces positive phase 2 data for AG10 in symptomatic patients with mutant or wild-type TTR amyloid cardiomyopathy. Accessed August 23, 2019. https:\/\/apnews.com\/cb91b444cf50c5963381779075e48989"},{"key":"bibr44-10600280211000351","unstructured":"Eidos Therapeutics. Efficacy and safety of AG10 in subjects with transthyretin amyloid cardiomyopathy (ATTRIBUTE-CM). Accessed October 9, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03860935"},{"key":"bibr45-10600280211000351","unstructured":"Prothena Biosciences Limited. A study of PRX004 in subjects with amyloid transthyretin (ATTR) amyloidosis. Accessed August 5, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03336580"},{"key":"bibr46-10600280211000351","unstructured":"Neurimmune AG. Neurimmune announces the initiation of a phase 1 study of NI006 for the treatment of ATTR cardiomyopathy. Accessed September 29, 2020. https:\/\/www.neurimmune.com\/news\/neurimmune-announces-the-initiation-of-a-phase-1-study-of-ni006-for-the-treatment-of-attr-cardiomyopathy"},{"key":"bibr47-10600280211000351","unstructured":"Neurimmune AG. First-in-human study of NI006 in patients with amyloid transthyretin cardiomyopathy. Accessed September 29, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04360434?term=NCT04360434&draw=2&rank=1"},{"key":"bibr48-10600280211000351","unstructured":"Alnylam Pharmaceuticals. A safety and tolerability study of an investigational drug, ALN-TTRSC02, in healthy subjects. Accessed September 30, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02797847?term=ALN-TTRSC02&draw=2"},{"key":"bibr49-10600280211000351","unstructured":"Alnylam Pharmaceuticals. HELIOS-A: a study of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Accessed September 30, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03759379"},{"key":"bibr50-10600280211000351","unstructured":"Alnylam Pharmaceuticals. HELIOS-B: a study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. Accessed September 30, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04153149"},{"key":"bibr51-10600280211000351","unstructured":"Alnylam Pharmaceuticals. Vutrisiran clinical development program. Accessed September 30, 2020. https:\/\/www.alnylam.com\/wp-content\/uploads\/pdfs\/HELIOS-Fact-Sheet.pdf"},{"key":"bibr52-10600280211000351","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.07.228"},{"key":"bibr53-10600280211000351","unstructured":"Ionis Pharmaceuticals Inc. CARDIO-TTRansform: a study to evaluate the efficacy and safety of AKCEA-TTR-LRx in participants with transthyretin-mediated amyloid cardiomyopathy (ATTRCM). Accessed October 5, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04136171?lead=ionis+pharmaceuticals&phase=2&draw=2"},{"key":"bibr54-10600280211000351","unstructured":"CRISPR Therapeutics. CRISPR\/Cas9\u2014a specific, efficient and versatile gene-editing technology we can harness to modify, delete or correct precise regions of our DNA. Accessed October 6, 2020. http:\/\/www.crisprtx.com\/gene-editing\/crispr-cas9"},{"key":"bibr55-10600280211000351","unstructured":"Intellia Therapeutics. Intellia Therapeutics highlights recent progress and anticipated 2020 milestones. Accessed October 1, 2020. https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-highlights-recent-progress-and-anticipated"},{"key":"bibr56-10600280211000351","unstructured":"Intellia Therapeutics. Intellia Therapeutics presents new preclinical data showing persistent in vivo editing and durability of effect following CRISPR\/Cas9-based treatment. Accessed October 1, 2020. https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-presents-new-preclinical-data-showing"},{"key":"bibr57-10600280211000351","unstructured":"Drugs.com. Vyndaqel prices, coupons and patient assistance programs. Accessed February 11, 2021. https:\/\/www.drugs.com\/price-guide\/vyndaqel"},{"key":"bibr58-10600280211000351","unstructured":"Drugs.com. Vyndamax prices, coupons and patient assistance programs. Accessed February 11, 2021. https:\/\/www.drugs.com\/price-guide\/vyndamax"},{"key":"bibr59-10600280211000351","unstructured":"Drugs.com. Tolcapone prices, coupons and patient assistance programs. Accessed February 11, 2021. https:\/\/www.drugs.com\/price-guide\/tolcapone"},{"key":"bibr60-10600280211000351","unstructured":"Drugs.com. Onpattro prices, coupons and patient assistance programs. Accessed February 11, 2021. https:\/\/www.drugs.com\/price-guide\/onpattro"},{"key":"bibr61-10600280211000351","unstructured":"Drugs.com. Tegsedi prices, coupons and patient assistance programs. Accessed February 11, 2021. https:\/\/www.drugs.com\/price-guide\/tegsedi"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211000351","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280211000351","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211000351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:07Z","timestamp":1777374967000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280211000351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/10600280211000351"],"URL":"https:\/\/doi.org\/10.1177\/10600280211000351","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]}}}